Company intelligence / Profile preview

Oxford Brain Diagnostics

Oxford, England, United Kingdomoxfordbraindiagnostics.com ↗

Ownership: Private
Development stage: Commercial

Overview

CDM Insights has received FDA clearance for clinical use in the US. The technology provides non-invasive measurement of brain microstructure from standard MRI scans to support early diagnosis and monitoring of neurodegenerative diseases. It has demonstrated strong correlation with disease staging in dementia. The company has begun commercial rollout across healthcare sectors in the UK and US.

Therapeutic areas: Neurology
Modalities: Digital diagnosticsMRI-based softwareImaging biomarkersDigital health tools
Industry: Medical Imaging

Partnerships

Strategic partnerships with pharmaceutical companies to support clinical trials/drug development by providing objective measures of patient brain health using their software.

Beyond the preview

Go deeper on Oxford Brain Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxford Brain Diagnostics.

Explore the full profile